HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
PHVS
Pharvaris NV
Healthcare Biotechnology ADR · Netherlands · Reports in eur
Market Cap: $2.31B
Market Cap
$2.31B
Enterprise Val
$1.94B
P/E Ratio
-11.67
P/B Ratio
6.63
Trailing PEG (1Y)
0.74
As Of
Aug 16, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value$343.3M
Return on Equity-61.01%
Return on Assets-55.64%
Debt/Equity0.00
LT Debt/Equity0.00
Revenue Per Share0.00

Income Statement

Jun 30, 2026
Revenue$0.00
Cost of Revenue$0.00
Gross Profit$0.00
R&D$39.8M
SG&A$17.9M
Operating Expenses$57.7M
Operating Income-$57.7M
Interest Expense-$4.0M
Tax Expense$684.3K
Net Income-$54.4M
EPS (Basic)$-0.80
EPS (Diluted)$-0.80
EBIT-$57.7M
EBITDA-$57.5M
Consolidated Income-$54.4M
Non-Controlling Interests$0.00

Balance Sheet

Jun 30, 2026
Cash & Equivalents$361.7M
Accounts Receivable$1.2M
Inventory$0.00
Current Assets$366.7M
LT Investments$0.00
Property, Plant & Equipment$1.4M
Intangibles$0.00
Non-Current Assets$6.8M
Total Assets$373.5M
Accounts Payable$3.2M
Current Debt$218.6K
LT Debt$547.0K
Total Liabilities$31.7M
Total Debt$765.6K
Retained Earnings-$759.7M
Shareholder Equity$341.8M
Shares Outstanding65,400,000

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow-$43.0M
Investing Cash Flow-$30.6K
Financing Cash Flow$120.3M
CapEx-$30.6K
Free Cash Flow-$43.0M
Depreciation & Amort.$203.7K
Stock-Based Comp$7.5M
Debt Issued/Repaid-$70.5K
Equity Issued/Repaid$128.6M
Net Change in Cash$77.3M
Data cached · Meta live · Daily live · Statements live · TTL 24h